These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1003214)

  • 1. The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
    Tyce GM
    J Neurochem; 1976 Dec; 27(6):1397-403. PubMed ID: 1003214
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of administration of 5-hydroxytryptophan and an inhibitor of L-aromatic amino acid decarboxylase on glucose metabolism in rat brain.
    Wong KL; Tyce GM
    Neurochem Res; 1979 Apr; 4(2):277-87. PubMed ID: 313531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 5. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
    Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
    Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
    [No Abstract]   [Full Text] [Related]  

  • 6. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
    Wong KL; Tyce GM
    Neurochem Res; 1979 Dec; 4(6):821-6. PubMed ID: 44547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM; Scheline RR
    J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential effect of benserazide on catecholamine concentrations in the rat pineal, cerebral cortex and hypothalamus.
    Ho AK; Smith JA
    Biochem Pharmacol; 1983 Dec; 32(23):3605-9. PubMed ID: 6651878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of benserazide on changes in monoamine oxidase activity in some rat tissues following treatment with L-DOPA.
    Callingham BA; Lyles GA
    J Auton Pharmacol; 1980 Nov; 1(1):9-16. PubMed ID: 7341636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The action L-dopa on sexual behaviour of male rats.
    Da Prada M; Carruba M; Saner A; O'Brien A; Pletscher A
    Brain Res; 1973 Jun; 55(2):383-9. PubMed ID: 4541349
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
    Messiha FS
    Br J Pharmacol; 1977 May; 60(1):55-7. PubMed ID: 884390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man].
    Balestreri R; Bertolini S; Elicio N; Costa S
    Boll Soc Ital Biol Sper; 1974 Jul; 50(12):832-7. PubMed ID: 4447697
    [No Abstract]   [Full Text] [Related]  

  • 17. Interaction of tetrahydropapaveroline with inhibition of dopa-decarboxylase by Ro 4-4602 in brain: effects on alcohol drinking in the rat.
    Miñano FJ; McMillen BA; Myers RD
    Alcohol; 1989; 6(2):133-7. PubMed ID: 2713086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A histochemical study on the central effect of monoamine precursors.
    Kato N; Murase Y
    Folia Psychiatr Neurol Jpn; 1975; 29(2):189-95. PubMed ID: 1080740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.